Prevail Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Prevail Therapeutics Inc.
The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Most of Lilly’s 2021 gains will come from its newer products, but sales of COVID-19 treatments added $500m to the company’s 2020 revenue guidance and may total $1bn-$2bn next year.
Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.
- Site Specific
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule